Christopher Wardell
Concepts (260)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Multiple Myeloma | 38 | 2023 | 3024 | 1.810 |
Why?
| Mutation | 21 | 2022 | 1499 | 1.760 |
Why?
| High-Throughput Nucleotide Sequencing | 5 | 2021 | 206 | 1.070 |
Why?
| Translocation, Genetic | 14 | 2021 | 286 | 1.040 |
Why?
| Oncogenes | 2 | 2018 | 63 | 0.790 |
Why?
| Biliary Tract Neoplasms | 1 | 2018 | 8 | 0.650 |
Why?
| Cholangiocarcinoma | 1 | 2018 | 30 | 0.640 |
Why?
| Gene Expression Profiling | 14 | 2022 | 1138 | 0.620 |
Why?
| Genomics | 8 | 2022 | 309 | 0.580 |
Why?
| Proto-Oncogene Proteins B-raf | 3 | 2022 | 90 | 0.560 |
Why?
| Gene Expression Regulation, Neoplastic | 11 | 2022 | 867 | 0.540 |
Why?
| Prognosis | 15 | 2021 | 2116 | 0.450 |
Why?
| Brain Neoplasms | 3 | 2023 | 284 | 0.430 |
Why?
| Gene Dosage | 5 | 2020 | 91 | 0.420 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2020 | 1061 | 0.410 |
Why?
| Plasma Cells | 4 | 2021 | 238 | 0.400 |
Why?
| Genetic Predisposition to Disease | 5 | 2018 | 575 | 0.400 |
Why?
| Genome, Human | 4 | 2021 | 132 | 0.380 |
Why?
| Evolution, Molecular | 2 | 2021 | 103 | 0.380 |
Why?
| Liver Neoplasms | 3 | 2022 | 353 | 0.370 |
Why?
| DNA Mutational Analysis | 7 | 2020 | 218 | 0.360 |
Why?
| Humans | 51 | 2023 | 54132 | 0.360 |
Why?
| Thalidomide | 5 | 2019 | 398 | 0.350 |
Why?
| DNA Copy Number Variations | 4 | 2021 | 114 | 0.350 |
Why?
| In Situ Hybridization, Fluorescence | 11 | 2023 | 277 | 0.340 |
Why?
| Monoclonal Gammopathy of Undetermined Significance | 4 | 2017 | 108 | 0.320 |
Why?
| Software | 2 | 2021 | 296 | 0.320 |
Why?
| Neoplasm Recurrence, Local | 3 | 2021 | 643 | 0.300 |
Why?
| Carcinoma, Hepatocellular | 2 | 2022 | 203 | 0.290 |
Why?
| Chromosome Aberrations | 6 | 2022 | 315 | 0.290 |
Why?
| Polymorphism, Single Nucleotide | 3 | 2018 | 558 | 0.280 |
Why?
| Clonal Evolution | 2 | 2019 | 60 | 0.270 |
Why?
| Epigenesis, Genetic | 4 | 2018 | 399 | 0.270 |
Why?
| Immunoglobulin Heavy Chains | 3 | 2014 | 54 | 0.270 |
Why?
| Chromosomes, Human, Pair 1 | 2 | 2019 | 113 | 0.270 |
Why?
| Neoplasm Proteins | 3 | 2017 | 367 | 0.250 |
Why?
| Disease Progression | 8 | 2021 | 915 | 0.250 |
Why?
| Gene Regulatory Networks | 2 | 2022 | 125 | 0.240 |
Why?
| Lymphoma, B-Cell, Marginal Zone | 1 | 2023 | 22 | 0.230 |
Why?
| Central Nervous System Neoplasms | 1 | 2023 | 57 | 0.230 |
Why?
| Polycomb Repressive Complex 2 | 2 | 2021 | 50 | 0.230 |
Why?
| Chromosomes, Human, Pair 14 | 5 | 2014 | 76 | 0.220 |
Why?
| Exome | 4 | 2017 | 52 | 0.220 |
Why?
| Male | 25 | 2021 | 27350 | 0.220 |
Why?
| Female | 26 | 2021 | 28437 | 0.210 |
Why?
| STAT2 Transcription Factor | 1 | 2021 | 7 | 0.210 |
Why?
| STAT1 Transcription Factor | 1 | 2021 | 27 | 0.210 |
Why?
| Li-Fraumeni Syndrome | 1 | 2021 | 13 | 0.210 |
Why?
| Germ-Line Mutation | 2 | 2021 | 68 | 0.210 |
Why?
| Hematologic Neoplasms | 1 | 2023 | 99 | 0.210 |
Why?
| Genome-Wide Association Study | 3 | 2018 | 198 | 0.200 |
Why?
| Middle Aged | 17 | 2021 | 13094 | 0.200 |
Why?
| Aged | 15 | 2021 | 10059 | 0.200 |
Why?
| Japan | 2 | 2018 | 25 | 0.200 |
Why?
| Gene Frequency | 2 | 2017 | 120 | 0.190 |
Why?
| Ecosystem | 1 | 2021 | 90 | 0.190 |
Why?
| Exosome Multienzyme Ribonuclease Complex | 1 | 2020 | 14 | 0.190 |
Why?
| Leukemia, Plasma Cell | 1 | 2020 | 34 | 0.190 |
Why?
| Glioblastoma | 1 | 2021 | 99 | 0.190 |
Why?
| Aged, 80 and over | 9 | 2021 | 3442 | 0.180 |
Why?
| Cell Cycle | 1 | 2021 | 274 | 0.180 |
Why?
| Neoplasms | 2 | 2020 | 1309 | 0.180 |
Why?
| DNA Methylation | 3 | 2016 | 575 | 0.180 |
Why?
| Chromosomal Instability | 1 | 2019 | 18 | 0.180 |
Why?
| Genes, myc | 1 | 2019 | 47 | 0.170 |
Why?
| Chromosomes, Human, Pair 4 | 3 | 2014 | 30 | 0.170 |
Why?
| Diploidy | 2 | 2017 | 30 | 0.170 |
Why?
| Chromosomes, Human, Pair 11 | 3 | 2014 | 54 | 0.170 |
Why?
| Cell Survival | 2 | 2018 | 661 | 0.160 |
Why?
| INDEL Mutation | 1 | 2018 | 5 | 0.160 |
Why?
| Italy | 1 | 2018 | 24 | 0.160 |
Why?
| Genes, Immunoglobulin Heavy Chain | 2 | 2019 | 14 | 0.160 |
Why?
| Mutagenesis | 1 | 2018 | 77 | 0.160 |
Why?
| Genes, Tumor Suppressor | 2 | 2021 | 85 | 0.160 |
Why?
| Adult | 13 | 2021 | 14196 | 0.160 |
Why?
| Chromosomes, Human, Pair 5 | 1 | 2017 | 16 | 0.160 |
Why?
| Histone-Lysine N-Methyltransferase | 2 | 2016 | 57 | 0.160 |
Why?
| Transcriptional Elongation Factors | 1 | 2017 | 28 | 0.160 |
Why?
| Enhancer Elements, Genetic | 1 | 2017 | 64 | 0.150 |
Why?
| Transcriptome | 4 | 2021 | 347 | 0.150 |
Why?
| Chromosomes, Human | 1 | 2017 | 45 | 0.150 |
Why?
| Reproducibility of Results | 1 | 2021 | 1307 | 0.150 |
Why?
| Melanoma | 1 | 2020 | 315 | 0.150 |
Why?
| B-Lymphocytes | 2 | 2016 | 176 | 0.140 |
Why?
| Neoplasms, Multiple Primary | 1 | 2016 | 45 | 0.140 |
Why?
| Hepatocytes | 1 | 2018 | 216 | 0.140 |
Why?
| Immunologic Factors | 1 | 2017 | 130 | 0.140 |
Why?
| Neoplasm Metastasis | 1 | 2016 | 252 | 0.140 |
Why?
| Melphalan | 2 | 2013 | 181 | 0.130 |
Why?
| Oligodendroglioma | 1 | 2015 | 10 | 0.130 |
Why?
| Endoribonucleases | 1 | 2015 | 15 | 0.130 |
Why?
| ras Proteins | 1 | 2015 | 69 | 0.130 |
Why?
| Sequence Analysis, DNA | 2 | 2016 | 277 | 0.130 |
Why?
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2015 | 44 | 0.130 |
Why?
| Endoplasmic Reticulum Stress | 1 | 2015 | 41 | 0.130 |
Why?
| Survival Rate | 4 | 2020 | 955 | 0.130 |
Why?
| SMN Complex Proteins | 1 | 2014 | 4 | 0.130 |
Why?
| Skin Neoplasms | 1 | 2020 | 530 | 0.130 |
Why?
| Survival Analysis | 5 | 2015 | 739 | 0.120 |
Why?
| RNA Processing, Post-Transcriptional | 1 | 2014 | 29 | 0.120 |
Why?
| Mutation Rate | 3 | 2021 | 40 | 0.120 |
Why?
| Cyclin D | 1 | 2013 | 20 | 0.120 |
Why?
| Chromosome Deletion | 2 | 2011 | 151 | 0.120 |
Why?
| Signal Transduction | 5 | 2022 | 1754 | 0.120 |
Why?
| Kaplan-Meier Estimate | 4 | 2018 | 514 | 0.120 |
Why?
| Transcription Factors | 2 | 2015 | 619 | 0.120 |
Why?
| Genes, erbB-1 | 1 | 2013 | 9 | 0.120 |
Why?
| RNA, Neoplasm | 1 | 2013 | 55 | 0.120 |
Why?
| Nerve Tissue Proteins | 1 | 2015 | 196 | 0.120 |
Why?
| Precursor Cells, B-Lymphoid | 1 | 2013 | 9 | 0.110 |
Why?
| Chromosome Breakage | 1 | 2013 | 19 | 0.110 |
Why?
| Germinal Center | 1 | 2013 | 23 | 0.110 |
Why?
| Cell Line, Tumor | 4 | 2022 | 1542 | 0.110 |
Why?
| RNA Splicing | 3 | 2021 | 38 | 0.110 |
Why?
| Repressor Proteins | 1 | 2014 | 167 | 0.110 |
Why?
| Genetic Heterogeneity | 1 | 2012 | 22 | 0.110 |
Why?
| Cell Transformation, Neoplastic | 1 | 2013 | 200 | 0.110 |
Why?
| DNA-Binding Proteins | 1 | 2015 | 463 | 0.100 |
Why?
| Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2011 | 28 | 0.100 |
Why?
| Acetyltransferases | 1 | 2011 | 23 | 0.100 |
Why?
| Chromosomes, Human, Pair 17 | 1 | 2011 | 43 | 0.100 |
Why?
| DNA, Neoplasm | 3 | 2018 | 172 | 0.100 |
Why?
| RNA, Messenger | 1 | 2015 | 1222 | 0.100 |
Why?
| Cell Proliferation | 3 | 2022 | 1099 | 0.100 |
Why?
| Antineoplastic Agents | 3 | 2018 | 1295 | 0.100 |
Why?
| Multivariate Analysis | 3 | 2021 | 646 | 0.090 |
Why?
| TOR Serine-Threonine Kinases | 1 | 2010 | 85 | 0.090 |
Why?
| Remission Induction | 2 | 2021 | 222 | 0.090 |
Why?
| Clone Cells | 2 | 2021 | 90 | 0.090 |
Why?
| Tumor Suppressor Protein p53 | 1 | 2011 | 251 | 0.090 |
Why?
| Phenotype | 3 | 2022 | 822 | 0.090 |
Why?
| MicroRNAs | 1 | 2013 | 387 | 0.090 |
Why?
| Alleles | 2 | 2021 | 278 | 0.080 |
Why?
| Spliceosomes | 2 | 2021 | 10 | 0.080 |
Why?
| Transcriptional Activation | 2 | 2021 | 134 | 0.080 |
Why?
| DNA | 1 | 2012 | 582 | 0.080 |
Why?
| Follow-Up Studies | 3 | 2020 | 2384 | 0.080 |
Why?
| Genomic Instability | 2 | 2018 | 95 | 0.070 |
Why?
| Epigenomics | 2 | 2017 | 67 | 0.070 |
Why?
| Risk Factors | 3 | 2021 | 3936 | 0.070 |
Why?
| Loss of Heterozygosity | 2 | 2018 | 97 | 0.070 |
Why?
| Disease-Free Survival | 2 | 2019 | 488 | 0.060 |
Why?
| Chromosomes, Human, Pair 20 | 2 | 2014 | 11 | 0.060 |
Why?
| Treatment Outcome | 4 | 2019 | 5596 | 0.060 |
Why?
| Protein Binding | 2 | 2017 | 743 | 0.060 |
Why?
| Genotype | 2 | 2017 | 607 | 0.060 |
Why?
| Dexamethasone | 2 | 2019 | 448 | 0.060 |
Why?
| Liver | 2 | 2022 | 1246 | 0.060 |
Why?
| Histones | 2 | 2016 | 331 | 0.060 |
Why?
| Proportional Hazards Models | 2 | 2015 | 428 | 0.050 |
Why?
| Janus Kinase 1 | 1 | 2021 | 20 | 0.050 |
Why?
| Janus Kinase 2 | 1 | 2021 | 31 | 0.050 |
Why?
| Gene Rearrangement | 1 | 2022 | 70 | 0.050 |
Why?
| Organoids | 1 | 2021 | 41 | 0.050 |
Why?
| Syndecan-1 | 1 | 2021 | 82 | 0.050 |
Why?
| Nitriles | 1 | 2021 | 71 | 0.050 |
Why?
| Microarray Analysis | 2 | 2012 | 83 | 0.050 |
Why?
| Biomarkers, Pharmacological | 2 | 2011 | 28 | 0.050 |
Why?
| Chromosome Mapping | 2 | 2011 | 176 | 0.050 |
Why?
| Pyrazoles | 1 | 2021 | 112 | 0.050 |
Why?
| Polymerase Chain Reaction | 2 | 2013 | 533 | 0.050 |
Why?
| Proto-Oncogene Proteins p21(ras) | 1 | 2021 | 69 | 0.050 |
Why?
| Alternative Splicing | 1 | 2021 | 63 | 0.050 |
Why?
| Cell Movement | 1 | 2022 | 276 | 0.050 |
Why?
| Gene Expression Regulation, Leukemic | 1 | 2020 | 36 | 0.050 |
Why?
| Cell Line | 2 | 2015 | 1166 | 0.050 |
Why?
| Phosphoproteins | 1 | 2021 | 116 | 0.050 |
Why?
| Pyrimidines | 1 | 2021 | 196 | 0.050 |
Why?
| Lymphoma, Follicular | 1 | 2020 | 30 | 0.050 |
Why?
| Gene Expression | 2 | 2013 | 667 | 0.050 |
Why?
| Protein Disulfide-Isomerases | 1 | 2019 | 15 | 0.040 |
Why?
| Recurrence | 1 | 2021 | 692 | 0.040 |
Why?
| Prospective Studies | 2 | 2016 | 2607 | 0.040 |
Why?
| Maintenance Chemotherapy | 1 | 2019 | 48 | 0.040 |
Why?
| Young Adult | 2 | 2021 | 4320 | 0.040 |
Why?
| Syndrome | 1 | 2019 | 253 | 0.040 |
Why?
| Transcription Elongation, Genetic | 1 | 2017 | 3 | 0.040 |
Why?
| Physical Chromosome Mapping | 1 | 2017 | 10 | 0.040 |
Why?
| Genetic Drift | 1 | 2017 | 3 | 0.040 |
Why?
| Gene Knockdown Techniques | 1 | 2018 | 127 | 0.040 |
Why?
| Unfolded Protein Response | 1 | 2017 | 30 | 0.040 |
Why?
| Genetic Loci | 1 | 2017 | 59 | 0.040 |
Why?
| Xenograft Model Antitumor Assays | 1 | 2018 | 219 | 0.040 |
Why?
| Caspases | 1 | 2018 | 147 | 0.040 |
Why?
| Molecular Targeted Therapy | 1 | 2018 | 130 | 0.040 |
Why?
| Mitosis | 1 | 2017 | 107 | 0.040 |
Why?
| Genetic Structures | 1 | 2016 | 1 | 0.040 |
Why?
| Virus Integration | 1 | 2016 | 9 | 0.040 |
Why?
| Genetic Association Studies | 1 | 2017 | 140 | 0.040 |
Why?
| Comparative Genomic Hybridization | 1 | 2016 | 50 | 0.040 |
Why?
| Risk | 1 | 2017 | 343 | 0.040 |
Why?
| Regulatory Sequences, Nucleic Acid | 1 | 2016 | 41 | 0.040 |
Why?
| Tumor Microenvironment | 1 | 2017 | 207 | 0.030 |
Why?
| Algorithms | 1 | 2020 | 697 | 0.030 |
Why?
| Computational Biology | 1 | 2018 | 231 | 0.030 |
Why?
| Nuclear Proteins | 1 | 2017 | 252 | 0.030 |
Why?
| Immunosuppressive Agents | 1 | 2017 | 249 | 0.030 |
Why?
| Minor Histocompatibility Antigens | 1 | 2015 | 16 | 0.030 |
Why?
| MafB Transcription Factor | 1 | 2015 | 11 | 0.030 |
Why?
| Cytidine Deaminase | 1 | 2015 | 13 | 0.030 |
Why?
| Proto-Oncogene Proteins c-maf | 1 | 2015 | 20 | 0.030 |
Why?
| RNA Stability | 1 | 2015 | 28 | 0.030 |
Why?
| Chromosomes, Human, Pair 16 | 1 | 2014 | 20 | 0.030 |
Why?
| Proto-Oncogene Proteins c-myc | 1 | 2015 | 55 | 0.030 |
Why?
| Multiplex Polymerase Chain Reaction | 1 | 2014 | 11 | 0.030 |
Why?
| Patient Selection | 1 | 2016 | 286 | 0.030 |
Why?
| Cytogenetic Analysis | 1 | 2014 | 89 | 0.030 |
Why?
| Ribonucleoproteins, Small Nuclear | 1 | 2014 | 6 | 0.030 |
Why?
| Amino Acid Sequence | 1 | 2016 | 777 | 0.030 |
Why?
| Single-Cell Analysis | 1 | 2014 | 56 | 0.030 |
Why?
| Introns | 1 | 2014 | 49 | 0.030 |
Why?
| Antibodies, Monoclonal | 1 | 2019 | 560 | 0.030 |
Why?
| Flow Cytometry | 1 | 2017 | 548 | 0.030 |
Why?
| Methylation | 1 | 2014 | 128 | 0.030 |
Why?
| Protein Isoforms | 1 | 2014 | 125 | 0.030 |
Why?
| High-Throughput Screening Assays | 1 | 2013 | 37 | 0.030 |
Why?
| Down-Regulation | 1 | 2015 | 392 | 0.030 |
Why?
| Base Sequence | 1 | 2015 | 732 | 0.030 |
Why?
| Time Factors | 1 | 2021 | 3223 | 0.030 |
Why?
| Protein Structure, Tertiary | 1 | 2014 | 289 | 0.030 |
Why?
| Osteonectin | 1 | 2013 | 12 | 0.030 |
Why?
| HeLa Cells | 1 | 2014 | 290 | 0.030 |
Why?
| Chromosomes, Human, Pair 7 | 1 | 2013 | 30 | 0.030 |
Why?
| Karyotyping | 1 | 2013 | 93 | 0.030 |
Why?
| Azacitidine | 1 | 2013 | 37 | 0.030 |
Why?
| Molecular Sequence Data | 1 | 2015 | 996 | 0.030 |
Why?
| Early Detection of Cancer | 1 | 2014 | 159 | 0.030 |
Why?
| Transforming Growth Factor beta1 | 1 | 2013 | 67 | 0.030 |
Why?
| Mass Spectrometry | 1 | 2014 | 312 | 0.030 |
Why?
| Homologous Recombination | 1 | 2013 | 43 | 0.030 |
Why?
| Validation Studies as Topic | 1 | 2012 | 10 | 0.030 |
Why?
| Tumor Suppressor Proteins | 1 | 2013 | 141 | 0.030 |
Why?
| Gene Library | 1 | 2012 | 50 | 0.030 |
Why?
| Laboratories | 1 | 2012 | 21 | 0.030 |
Why?
| Hemizygote | 1 | 2011 | 6 | 0.030 |
Why?
| Disease Models, Animal | 1 | 2018 | 1645 | 0.030 |
Why?
| Drug Resistance, Neoplasm | 1 | 2013 | 309 | 0.030 |
Why?
| Apoptosis | 1 | 2018 | 1306 | 0.030 |
Why?
| Predictive Value of Tests | 1 | 2014 | 1053 | 0.030 |
Why?
| Bone Marrow | 1 | 2013 | 415 | 0.020 |
Why?
| Prednisolone | 1 | 2010 | 56 | 0.020 |
Why?
| Breast Neoplasms | 1 | 2020 | 1248 | 0.020 |
Why?
| Animals | 2 | 2018 | 14435 | 0.020 |
Why?
| Vincristine | 1 | 2010 | 98 | 0.020 |
Why?
| Cluster Analysis | 1 | 2010 | 250 | 0.020 |
Why?
| Cyclophosphamide | 1 | 2010 | 171 | 0.020 |
Why?
| Precancerous Conditions | 1 | 2010 | 93 | 0.020 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2011 | 473 | 0.020 |
Why?
| Adolescent | 1 | 2021 | 6890 | 0.020 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2010 | 153 | 0.020 |
Why?
| Stem Cell Transplantation | 1 | 2010 | 196 | 0.020 |
Why?
| Clinical Trials as Topic | 1 | 2012 | 489 | 0.020 |
Why?
| Child | 1 | 2021 | 7312 | 0.020 |
Why?
| Doxorubicin | 1 | 2010 | 258 | 0.020 |
Why?
| Sex Factors | 1 | 2011 | 770 | 0.020 |
Why?
| Up-Regulation | 1 | 2010 | 514 | 0.020 |
Why?
| Models, Biological | 1 | 2012 | 824 | 0.020 |
Why?
| Risk Assessment | 1 | 2013 | 1363 | 0.020 |
Why?
| Prevalence | 1 | 2011 | 1023 | 0.020 |
Why?
| Mice | 1 | 2018 | 6436 | 0.020 |
Why?
|
|
Wardell's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|